[go: up one dir, main page]

WO2005108993A3 - Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 6 (map3k6) - Google Patents

Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 6 (map3k6) Download PDF

Info

Publication number
WO2005108993A3
WO2005108993A3 PCT/EP2005/004553 EP2005004553W WO2005108993A3 WO 2005108993 A3 WO2005108993 A3 WO 2005108993A3 EP 2005004553 W EP2005004553 W EP 2005004553W WO 2005108993 A3 WO2005108993 A3 WO 2005108993A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
kinase
map3k6
compounds
mitogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2005/004553
Other languages
French (fr)
Other versions
WO2005108993A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Andreas Geerts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Publication of WO2005108993A2 publication Critical patent/WO2005108993A2/en
Publication of WO2005108993A3 publication Critical patent/WO2005108993A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a human MAP3K6 which is associated with cardiovascular diseases, (eg. Myocardial infarction) infections, (eg. Monocytes HIV-1 infected) dermatological diseases, endocrinological diseases, metabolic diseases, cancer, (eg. Thyroid, esophagus, stomach, colon, ileum, rectum, liver, uterus, ovary, breast, prostate, kidney tumor) gastroenterological diseases, inflammation, (eg. Liver cirrhosis, bening prostatic hyperplasia) hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, dermatological diseases, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, inflammation, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of MAP3K6 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2005/004553 2004-05-11 2005-04-28 Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 6 (map3k6) Ceased WO2005108993A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04011156.9 2004-05-11
EP04011156 2004-05-11

Publications (2)

Publication Number Publication Date
WO2005108993A2 WO2005108993A2 (en) 2005-11-17
WO2005108993A3 true WO2005108993A3 (en) 2006-06-15

Family

ID=34967468

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/004553 Ceased WO2005108993A2 (en) 2004-05-11 2005-04-28 Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 6 (map3k6)

Country Status (1)

Country Link
WO (1) WO2005108993A2 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035837A2 (en) * 2001-10-23 2003-05-01 Sagres Discovery Novel compositions and methods for cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035837A2 (en) * 2001-10-23 2003-05-01 Sagres Discovery Novel compositions and methods for cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KAISER ROBERT A ET AL: "Targeted inhibition of p38 mitogen-activated protein kinase antagonizes cardiac injury and cell death following ischemia-reperfusion in vivo.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 9 APR 2004, vol. 279, no. 15, 9 April 2004 (2004-04-09), pages 15524 - 15530, XP002343816, ISSN: 0021-9258 *
OMURA TAKASHI ET AL: "Involvement of apoptosis signal-regulating kinase-1 on angiotensin II-induced monocyte chemoattractant protein-1 expression.", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. FEB 2004, vol. 24, no. 2, February 2004 (2004-02-01), pages 270 - 275, XP002343817, ISSN: 1524-4636 *
WANG X S ET AL: "MAPKKK6, a novel mitogen-activated protein kinase kinase kinase, that associates with MAPKKK5", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 253, no. 1, 9 December 1998 (1998-12-09), pages 33 - 37, XP002169311, ISSN: 0006-291X *

Also Published As

Publication number Publication date
WO2005108993A2 (en) 2005-11-17

Similar Documents

Publication Publication Date Title
WO2005106012A3 (en) Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
WO2005031346A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor1 (adipor1)
WO2005108993A3 (en) Diagnostics and therapeutics for diseases associated with mitogen-activated protein kinase kinase kinase 6 (map3k6)
WO2005118833A3 (en) Diagnostics and therapeutics for diseases associated with sterile-alpha motif and leucine zipper containing kinase (zak)
WO2005050225A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 84 (gpr84)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2006010514A3 (en) Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5)
WO2005040211A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 1 (gpr1)
WO2005078117A3 (en) Diagnostics and therapeutics for diseases associated with kallikrein 6 (klk6)
WO2005085466A3 (en) Diagnostic and therapeutics for diseases associated with rho-associated protein kinase 2 (rock2)
WO2005059546A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 35 (gpr35)
WO2004086052A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a2b (adora2b)
WO2005114210A8 (en) Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3)
WO2005075675A3 (en) Diagnostics and therapeutics for diseases associated with putative cysteine protease 1 (prs1)
WO2005090994A3 (en) Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1)
WO2006005462A3 (en) Diagnostics and therapeutics for diseases associated with tyrosine kinase wee 1 (wee1)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)
WO2005054866A3 (en) Diagnostics and therapeutics for diseases associated with two-pore domain potassium channel (kcnk2)
WO2005040822A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 25 (gpr25)
WO2004080374A3 (en) Diagnostics and therapeutics for diseases associated with phosphodi-esterase 1c (pde1c)
WO2005093091A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26)
WO2004106934A3 (en) Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine (serotonin) receptor 7 (5-ht7)
WO2004106935A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 103 (gpr103)
WO2005106486A3 (en) Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3)
WO2005059558A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor mc4 (mc4)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase